




RealRate

PHARMACEUTICAL 2016

ELI Lilly Co
Rank 182 of 295

Lilly



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 17% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	12,573,600
Cost of Goods Sold	0
Intangible Assets	9,074,700
Liabilities, Current	8,229,600
Liabilities, Non-Current	12,749,000
Other Assets	5,867,100
Other Compr. Net Income	-588,900
Other Expenses	6,220,900
Other Liabilities	0
Other Net Income	0
Other Revenues	19,958,700
Property and Equipment	8,053,500
Research and Development	4,796,400
Selling, General and Administrative Expense	6,533,000

Output Variable	Value in 1000 USD
Assets	35,568,900
Liabilities	20,978,600
Expenses	17,550,300
Revenues	19,958,700
Stockholders Equity	14,590,300
Net Income	2,408,400
Comprehensive Net Income	2,113,950
BaseVar	47,322,700
ECR before Limited Liability	120%
Economic Capital Ratio	246%